Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial.
Acute heart failure
Pharmacotherapy
Sex differences
Sex-specific therapy approach
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
revised:
24
09
2023
received:
02
04
2023
accepted:
14
10
2023
pubmed:
24
10
2023
medline:
24
10
2023
entrez:
23
10
2023
Statut:
aheadofprint
Résumé
Sex-specific differences in acute heart failure (AHF) are both relevant and underappreciated. Therefore, it is crucial to evaluate the risk/benefit ratio and the implementation of novel AHF therapies in women and men separately. We performed a pre-defined sex-specific analysis in AHF patients randomized to a strategy of early intensive and sustained vasodilatation versus usual care in an international, multicentre, open-label, blinded endpoint trial. Inclusion criteria were AHF with increased plasma concentrations of natriuretic peptides, systolic blood pressure ≥100 mmHg, and plan for treatment in a general ward. Among 781 eligible patients, 288 (37%) were women. Women were older (median 83 vs. 76 years), had a lower body weight (median 64.5 vs. 77.6 kg) and lower estimated glomerular filtration rate (median 48 vs. 54 ml/min/1.73 m Rapid up-titration of RAAS inhibitors was less successfully implemented in women possibly explaining their higher rate of all-cause mortality and rehospitalization for AHF. ClinicalTrials.gov, unique identifier NCT00512759.
Banques de données
ClinicalTrials.gov
['NCT00512759']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Swiss National Science Foundation, the Swiss Heart Foundation
ID : FF22112
Organisme : the University of Basel
Organisme : the University Hospital Basel
Organisme : the STANLEY THOMAS JOHNSON Foundation
Investigateurs
Bojidar Dimov
(B)
Sabine Hartwiger
(S)
Beat Müller
(B)
Bettina Glatz
(B)
Ronny Ziller
(R)
Rahel Isenrich
(R)
Tamina Mosimann
(T)
Jasper Boeddinghaus
(J)
Thomas Nestelberger
(T)
Christian Puelacher
(C)
Jasmin Martin
(J)
Ivo Strebel
(I)
Carmela Schumacher
(C)
Katharina Rentsch
(K)
Aline Bossa
(A)
Sergio Jallad
(S)
Alexandre Soeiro
(A)
Dimitar Georgiev
(D)
Thomas Jansen
(T)
Matthias Bossard
(M)
Michael Christ
(M)
David Conen
(D)
Paul Erne
(P)
Ioannis Kapos
(I)
Informations de copyright
© 2023 European Society of Cardiology.
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM, et al. Sex differences in heart failure. Eur Heart J 2019;40:3859-3868c. https://doi.org/10.1093/eurheartj/ehz835
Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002;106:3068-3072. https://doi.org/10.1161/01.cir.0000039105.49749.6f
Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996-1004. https://doi.org/10.1001/jamainternmed.2015.0924
Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018;39:3439-3450. https://doi.org/10.1093/eurheartj/ehy531
Tromp J, Lim SL, Tay WT, Teng THK, Chandramouli C, Ouwerkerk W, et al.; ASIAN-HF Investigators. Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care 2019;42:1792-1799. https://doi.org/10.2337/dc18-2515
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48:143-157. https://doi.org/10.2165/00003088-200948030-00001
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, et al.; ASIAN-HF Investigators. Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study. Lancet 2019;394:1254-1263. https://doi.org/10.1016/S0140-6736(19)31792-1
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al.; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455-462. https://doi.org/10.1093/eurheartj/ehv464
Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, et al.; GALACTIC Investigators. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: The GALACTIC randomized clinical trial. JAMA 2019;322:2292-2302. https://doi.org/10.1001/jama.2019.18598
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al.; ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442. https://doi.org/10.1093/eurheartj/ehn309
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975. https://doi.org/10.1002/ejhf.592
Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115. https://doi.org/10.2307/2529712
Vader JM, LaRue SJ, Stevens SR, Mentz RJ, DeVore AD, Lala A, et al. Timing and causes of readmission after acute heart failure hospitalization - Insights from the Heart Failure Network trials. J Card Fail 2016;22:875-883. https://doi.org/10.1016/j.cardfail.2016.04.014
Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 2017;19:627-634. https://doi.org/10.1002/ejhf.785
Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2014;2:429-436. https://doi.org/10.1016/j.jchf.2014.04.006
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF. Circulation 2020;141:338-351. https://doi.org/10.1161/CIRCULATIONAHA.119.044491
Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, et al. Sex-based differences in heart failure across the ejection fraction spectrum: Phenotyping, and prognostic and therapeutic implications. JACC Heart Fail 2019;7:505-515. https://doi.org/10.1016/j.jchf.2019.03.011
Motiejūnaitė J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi DJ, et al. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. Eur Heart J 2020;41:1357-1364. https://doi.org/10.1093/eurheartj/ehaa071
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. Lancet 2022;400:1938-1952. https://doi.org/10.1016/S0140-6736(22)02076-1
Veenis JF, Rocca HPBL, Linssen GCM, Erol-Yilmaz A, Pronk ACB, Engelen DJM, et al.; CHECK-HF Investigators. Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. Eur J Prev Cardiol 2021;28:957-965. https://doi.org/10.1177/2047487320923185
Bots SH, Onland-Moret NC, Tulevski II, van der Harst P, Cramer MJM, Asselbergs FW, et al. Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart 2021;107:1748-1755. https://doi.org/10.1136/heartjnl-2021-319229
Whitelaw S, Sullivan K, Eliya Y, Alruwayeh M, Thabane L, Yancy CW, et al. Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review. Eur J Heart Fail 2021;23:15-24. https://doi.org/10.1002/ejhf.2034
Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women's participation in cardiovascular clinical trials from 2010 to 2017. Circulation 2020;141:540-548. https://doi.org/10.1161/CIRCULATIONAHA.119.043594
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. https://doi.org/10.1056/NEJMoa1409077
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al.; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-548. https://doi.org/10.1056/NEJMoa1812851